BackCerevel Therapeutics Holdings Overview

Cerevel Therapeutics Holdings Total Assets

Latest total assets for CERE: $1.1B.

Get informed when a big investor buys or sells

+ Follow
Total Assets
$1.13B
21.17% YoYΔ $197.00M vs prior year quarter

Peer average

Loading

Cerevel Therapeutics Holdings Total Assets History

Loading

Cerevel Therapeutics Holdings vs. peers: Total Assets Comparison

Loading

Cerevel Therapeutics Holdings Total Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Cerevel Therapeutics Holdings (CERE) FAQ

Cerevel Therapeutics Holdings (CERE) currently reports a total assets of $1.1B as of March 2024. That compares with $930M in the prior-year period — up 21.2% year over year. Use the charts on this page to explore Cerevel Therapeutics Holdings's total assets history and peer comparisons.

Cerevel Therapeutics Holdings's total assets increased from $930M to $1.1B — a 21.2% year-over-year increase (period ending March 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Cerevel Therapeutics Holdings reported $1.1B in total assets as of March 2024. That compares with $930M in the prior-year period — up 21.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total assets of $1.1B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Cerevel Therapeutics Holdings, and consider following CERE for alerts when major investors trade the stock.

Cerevel Therapeutics Holdings is classified in the Healthcare sector. On total assets, it currently shows $1.1B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CERE with unrelated industries.